Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oragenics has been notified by the European Patent Office of its intention to grant a European patent for the company's in vivo induced antigen technology, IVIAT. Oragenics intends to validate the patent in key European jurisdictions.
Subscribe to our email newsletter
According to Oragenics, IVIAT is a unique discovery platform designed to identify genes of pathogenic bacteria that are specifically present when humans have infections.
Robert Zahradnik, president and CEO of Oragenics, said: “The IVIAT technology has already proven its ability to identify novel targets for such infectious agents as Vibrio cholerae (cholera), Escherichia coli (E. coli) and Pseudomonas aeruginosa, which cause infections in persons with compromised immune systems in addition to causing one out of 10 hospital acquired infections. These gene targets offer the promise of new diagnostic tests and vaccines. The granting of this EU patent will further add to our growing international patent portfolio.”